Somaxon To Put Silenor Phase III Program To Bed In December
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm's Q3 2007 filing timeframe puts it ahead of Neurocrine's resubmission plans for immediate-release indiplon.
You may also be interested in...
Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008
FDA asks firm to submit findings of a 26-week mouse toxicity study along with NDA, Somaxon tells “The Pink Sheet” DAILY.
Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008
FDA asks firm to submit findings of a 26-week mouse toxicity study along with NDA, Somaxon tells “The Pink Sheet” DAILY.
Vanda Moves Ahead With Development Of Iloperidone, VEC-162
Following an end-of-Phase II meeting with FDA, Vanda plans to initiate a Phase III study of VEC-162 in sleep disorders in third quarter.